Saya, Sibel http://orcid.org/0000-0002-4796-6852
Chondros, Patty http://orcid.org/0000-0003-0393-8734
Abela, Anastasia http://orcid.org/0000-0003-2172-3294
Mihalopolous, Cathrine http://orcid.org/0000-0002-7127-9462
Chatterton, Mary Lou http://orcid.org/0000-0003-4902-9448
Gunn, Jane http://orcid.org/0000-0001-8836-7525
Chen, Timothy F. http://orcid.org/0000-0003-4189-8403
Polasek, Thomas M. http://orcid.org/0000-0003-1008-5223
Dettmann, Elise http://orcid.org/0009-0002-0775-4051
Brooks, Rachel http://orcid.org/0000-0002-8484-335X
King, Michelle http://orcid.org/0000-0002-3508-6559
Spencer, Luke http://orcid.org/0000-0003-4153-9048
Alphonse, Pavithran http://orcid.org/0000-0002-7238-685X
Milton, Shakira http://orcid.org/0000-0002-8510-6351
Ramsay, Georgia http://orcid.org/0000-0002-9408-8028
Siviour, Zoe http://orcid.org/0000-0001-8573-9979
Liew, Jamie http://orcid.org/0000-0002-9578-1078
Ly, Philip http://orcid.org/0000-0002-9828-6750
Thoenig, Matthew http://orcid.org/0000-0002-2059-4753
Seychell, Raushaan
La Rocca, Floriana
Hesson, Luke B.
Mejias, Nydia
Sivertsen, Terri
Galea, Melanie Anne
Bousman, Chad http://orcid.org/0000-0001-6303-8696
Emery, Jon http://orcid.org/0000-0002-5274-6336
Funding for this research was provided by:
MRFF (MRF1200060)
Article History
Received: 1 May 2023
Accepted: 6 May 2023
First Online: 19 May 2023
Declarations
:
: The PRESIDE Trial has been approved by the UoM HREC and received institutional governance and sponsorship authorisation via the UoM Research Governance Office before commencement.The University of Melbourne Ethics Committee ID number: 20626.Services Australia ID number: RMS1620.
: Not applicable. No identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. Informed consent materials are attached as supplementary materials.
: Sonic Healthcare (with Translational Software) currently has a commercially available pharmacogenomic test. To mitigate this conflict of interest, Sonic Healthcare and Translational Software will not have contact with GPs or participants. Identification of GPs and participants will be kept confidential within the PRESIDE study team. Chad Bousman is the founder and CEO of Sequence2Script Inc.